<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
    <PubmedArticle>
        <MedlineCitation Status="MEDLINE" Owner="NLM">
            <PMID Version="1">38123456</PMID>
            <DateCompleted>
                <Year>2024</Year>
                <Month>03</Month>
                <Day>15</Day>
            </DateCompleted>
            <Article PubModel="Print-Electronic">
                <Journal>
                    <ISSN IssnType="Electronic">1476-5578</ISSN>
                    <JournalIssue CitedMedium="Internet">
                        <Volume>29</Volume>
                        <Issue>3</Issue>
                        <PubDate>
                            <Year>2024</Year>
                            <Month>Mar</Month>
                        </PubDate>
                    </JournalIssue>
                    <Title>Molecular psychiatry</Title>
                    <ISOAbbreviation>Mol Psychiatry</ISOAbbreviation>
                </Journal>
                <ArticleTitle>EEG biomarkers in fragile X syndrome: a comprehensive review of spectral and connectivity measures.</ArticleTitle>
                <Pagination>
                    <StartPage>789</StartPage>
                    <EndPage>802</EndPage>
                    <MedlinePgn>789-802</MedlinePgn>
                </Pagination>
                <Abstract>
                    <AbstractText Label="BACKGROUND">Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability and autism spectrum disorder. Electroencephalography (EEG) has emerged as a promising tool for identifying biomarkers in FXS.</AbstractText>
                    <AbstractText Label="METHODS">We conducted a systematic review of 45 studies examining EEG measures in individuals with FXS. We evaluated spectral power, event-related potentials, and connectivity measures.</AbstractText>
                    <AbstractText Label="RESULTS">Consistent findings include elevated gamma power, reduced alpha power, and altered auditory evoked potentials. Connectivity analyses reveal reduced long-range coherence and increased local connectivity.</AbstractText>
                    <AbstractText Label="CONCLUSIONS">EEG biomarkers show promise for clinical trials in FXS. Gamma power and auditory habituation are the most reliable measures, with effect sizes suitable for use as endpoints.</AbstractText>
                </Abstract>
                <AuthorList CompleteYN="Y">
                    <Author ValidYN="Y">
                        <LastName>Pedapati</LastName>
                        <ForeName>Ernest V</ForeName>
                        <Initials>EV</Initials>
                        <AffiliationInfo>
                            <Affiliation>Division of Child Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Ethridge</LastName>
                        <ForeName>Lauren E</ForeName>
                        <Initials>LE</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Psychology, University of Oklahoma, Norman, OK, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                    <Author ValidYN="Y">
                        <LastName>Sweeney</LastName>
                        <ForeName>John A</ForeName>
                        <Initials>JA</Initials>
                        <AffiliationInfo>
                            <Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH, USA.</Affiliation>
                        </AffiliationInfo>
                    </Author>
                </AuthorList>
                <Language>eng</Language>
                <PublicationTypeList>
                    <PublicationType UI="D016428">Journal Article</PublicationType>
                    <PublicationType UI="D016454">Review</PublicationType>
                    <PublicationType UI="D000078182">Systematic Review</PublicationType>
                </PublicationTypeList>
                <ArticleDate DateType="Electronic">
                    <Year>2024</Year>
                    <Month>01</Month>
                    <Day>15</Day>
                </ArticleDate>
            </Article>
            <MeshHeadingList>
                <MeshHeading>
                    <DescriptorName UI="D005600" MajorTopicYN="Y">Fragile X Syndrome</DescriptorName>
                    <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
                    <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName>
                    <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                </MeshHeading>
                <MeshHeading>
                    <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
                </MeshHeading>
            </MeshHeadingList>
        </MedlineCitation>
        <PubmedData>
            <ArticleIdList>
                <ArticleId IdType="pubmed">38123456</ArticleId>
                <ArticleId IdType="doi">10.1038/s41380-024-02456-7</ArticleId>
                <ArticleId IdType="pmc">PMC10987654</ArticleId>
            </ArticleIdList>
        </PubmedData>
    </PubmedArticle>
</PubmedArticleSet>
